Brands, Medical Use, Clinical Data
- Capsule (100, 200, 500, 750 mg)
Brands / Synonyms
Aethyl-chlorvynol; Alvinol; Arvynol; Etchlorvinolo; Ethchlorovynol; Ethchlorvinol; Ethchlorvinyl; Ethclorvynol; Ethochlorvynol; Ethychlorvynol; Normonson; Normosan; Normoson; Nostel; Nromoson; Placidil; Placidyl; Roeridorm; Serenesil; Serenil; Serensil; Serensiloline
Used for short-term hypnotic therapy in the management of insomnia for periods of up to one week in duration; however, this medication generally has been replaced by other sedative-hypnotic agents.
Ethchlorvynol is a sedative drug and schedule IV (USA) controlled substance. It produces cerebral depression, however the exact mechanism of action is not known.
Mechanism of Action
Although the exact mechanism of action is unknown, ethchlorvynol appears to depress the central nervous system in a manner similar to that of barbiturates. Barbiturates bind at a distinct binding sites associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
Rapidly absorbed from gastrointestinal tract.
Symptoms of overdose include thrombocytopenia.
Biotrnasformation / Drug Metabolism
About 90% of a dose is metabolized in the liver. Some ethchlorvynol may also be metabolized in the kidneys. Ethchlorvynol and metabolites undergo extensive enterohepatic recirculation.
Contraindicated in patients exhibiting hypersensitivity to this drug, in patients with severe pain, and in patients with porphyria.
Dicumarol and warfarin may decrease hypoprothrombinemic effect. Other depressasnts such as alcohol, barbiturates, and MAOIs may enhance CNS depression when administered with ethchlorvynol.